<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047471</url>
  </required_header>
  <id_info>
    <org_study_id>2021BY01</org_study_id>
    <nct_id>NCT05047471</nct_id>
  </id_info>
  <brief_title>To Improve the Ability of Early Screening and Diagnosis in Patients With Diabetic Nephropathy</brief_title>
  <official_title>Healthy China - The Improvement Projects for the Screening Ability of Diabetes and Its Complications And for the Standardized Ability of Diagnosis and Treatment for Patients With Early Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yiming Mu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Great Physician Commonweal Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a large-scale, multi-center, observational study. It is planned to establish a large&#xD;
      database of 10,000 patients with type 2 diabetes mellitus to investigate the prevalence,&#xD;
      awareness and screening rates of diabetes kidney disease (DKD), and provide real-world data&#xD;
      on the efficacy and safety of sodium glucose cotransporter 2 inhibitors (SGLT2i) in patients&#xD;
      with type 2 diabetes mellitus (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among the various complications of diabetes mellitus, DKD is considered as a major threat and&#xD;
      is one of the manifestations of diabetic microangiopathy. it is one of the main causes of&#xD;
      death for patients with T2DM.&#xD;
&#xD;
      Albuminuria is the earliest manifestation of DKD, which is mostly asymptomatic at the early&#xD;
      stage, if the albuminuria is poorly controlled, it may develop into clinical DKD. Therefore,&#xD;
      it is very important to improve the patients' awareness of DKD, regularly screen early kidney&#xD;
      diseases and use drugs rationally.&#xD;
&#xD;
      In order to promote the standardization of diagnosis and treatment of patients with DKD,&#xD;
      improve the knowledge and screening rate of patients with DKD, help the formation of health&#xD;
      literacy, healthy behavior and lifestyle, the investigators planned the study.&#xD;
&#xD;
      STUDY OBJECTIVES:&#xD;
&#xD;
        1. To understand the epidemiological disease burden of DKD in China, and to investigate the&#xD;
           prevalence rate, awareness rate and screening rate of DKD;&#xD;
&#xD;
        2. To understand the treatment status of patients with DKD in China;&#xD;
&#xD;
        3. To provide real-world data on the efficacy and safety of SGLT2i in the treatment of DKD&#xD;
           in China;&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of DKD</measure>
    <time_frame>at the time of screening</time_frame>
    <description>Prevalence of DKD (UACR &gt; 30 mg/g); The prevalence of microalbuminuria (30 mg/g ≤ UACR ≤ 300 mg/g); The prevalence of massive proteinuria (UACR &gt; 300 mg/g).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Awareness rate</measure>
    <time_frame>at the time of screening</time_frame>
    <description>Awareness rate=(The number of people who know their abnormal albuminuria)/(The number of people with diabetes mellitus complicated with albuminuria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Screening rate</measure>
    <time_frame>at the time of screening</time_frame>
    <description>Screening rate=(The number of people @who have checked urine protein within one year)/(The number of people involved in total diabetes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prescription proportion of various anti-diabetic drugs for patients with DKD</measure>
    <time_frame>at the time of screening</time_frame>
    <description>Prescription ratio of a certain hypoglycemic agent =(The number of people using a certain hypoglycemic agent)/(Total number of DKD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>risk factors of albuminuria: medication categories</measure>
    <time_frame>at the time of screening</time_frame>
    <description>Assess whether taking different categories of medications is a risk factor for albuminuria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>risk factors of albuminuria: Course of disease</measure>
    <time_frame>at the time of screening</time_frame>
    <description>It is defined as the years of diagnosis of diabetes. According to the &quot;Date of Diagnosis&quot; in the questionnaire collected during the screening, the course years of diabetes patients are divided into quartiles for evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>risk factors of albuminuria: Age</measure>
    <time_frame>at the time of screening</time_frame>
    <description>According to the &quot;date of birth&quot; in the questionnaire collected during the screening, the age of diabetic patients is divided into quartiles for evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>risk factors of albuminuria: Current smoking</measure>
    <time_frame>at the time of screening</time_frame>
    <description>According to the &quot;Current smoking&quot; in the questionnaire collected during the screening to evaluate whether smoking is the risk of albuminuria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>risk factors of albuminuria: gender</measure>
    <time_frame>at the time of screening</time_frame>
    <description>According to the &quot;gender&quot; in the questionnaire collected during the screening to evaluate whether gender is the risk of albuminuria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>risk factors of albuminuria: Drinking</measure>
    <time_frame>at the time of screening</time_frame>
    <description>According to the &quot; Drinking &quot; in the questionnaire collected during the screening to evaluate whether Drinking is the risk of albuminuria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>risk factors of albuminuria: Glycosylated hemoglobin</measure>
    <time_frame>at baseline</time_frame>
    <description>Baseline glycosylated hemoglobin is divided into quartiles for evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>risk factors of albuminuria: Hypertension</measure>
    <time_frame>at baseline</time_frame>
    <description>It is defined as the adults' systolic blood pressure which is greater than or equal to 140mmHg and/or diastolic blood pressure which is greater than or equal to 90mmHg. &quot;hypertension&quot; and &quot;non-hypertension&quot; for evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>risk factors of albuminuria: Increase in Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>at baseline</time_frame>
    <description>It is defined as more than 3.37mmol/L, &quot;elevated&quot; and &quot;normal&quot; for evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MD of the change of UACR</measure>
    <time_frame>at 6 months</time_frame>
    <description>the mean difference of the change of UACR from baseline between SGLT2i and non-SGLT2i group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OR of the incidence of the adverse events</measure>
    <time_frame>at 6 months</time_frame>
    <description>the odds ratio of the incidence of the adverse events of interest during the 6-month observation period between SGLT2i and non-SGLT2i group</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MD of the Percentage change of HbA1c</measure>
    <time_frame>at 6 months</time_frame>
    <description>the mean difference of the Percentage change from baseline of HbA1c between SGLT2i group and non-SGLT2i group</description>
  </other_outcome>
  <other_outcome>
    <measure>MD the Percentage change from baseline of other laboratory test parameters of interest</measure>
    <time_frame>at 6 months</time_frame>
    <description>the mean difference of the Percentage change from baseline of other laboratory test parameters of interest in SGLT2i group and non-SGLT2i group</description>
  </other_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Continuous screening of type 2 diabetic patients from the endocrinology outpatients of 50&#xD;
        hospitals across the country&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  It is known that patients with T2DM has a history of more than 12 months (the WHO1999&#xD;
             Standard) and is treated with at least one anti-diabetic agent.&#xD;
&#xD;
          -  Gender and age: men and women who are at least 18 years old with informed consent.&#xD;
&#xD;
          -  Patients are willing and able to provide written informed consent before participating&#xD;
             in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus (DM)&#xD;
&#xD;
          -  Patients with severe ketosis, diabetic coma, severe infection or severe trauma&#xD;
&#xD;
          -  Perioperative patients&#xD;
&#xD;
          -  Patients with severe renal impairment and advanced nephropathy (eGFR &lt; 45&#xD;
             ml/min/1.73m2)&#xD;
&#xD;
          -  Renal transplant patients&#xD;
&#xD;
          -  Patients are participating in or have participated in any other clinical trials in the&#xD;
             past 3 months&#xD;
&#xD;
          -  Any disease with a life expectancy of less than 2 years according to the clinical&#xD;
             judgment of the investigator&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients judged by the investigator to be unsuitable for participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yimin Mu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Medical Center of Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yimin Mu, MD</last_name>
    <phone>+86 13910580089</phone>
    <email>muyiming@301hospital.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Airport Area of Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongwei Gao, MD</last_name>
      <phone>+86 13801381273</phone>
      <email>gaohw@bjmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Haidian Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Huang, MD</last_name>
      <phone>+86 13621273878</phone>
      <email>hdyynfm@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Luhe Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dong Zhao, MD</last_name>
      <phone>+86 18911598827</phone>
      <email>zdoc66@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital Yanqing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jinzhan Song, MD</last_name>
      <phone>+86 15811096083</phone>
      <email>jinzhan2001@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tianpei Hong, MD</last_name>
      <phone>+86 13683265725</phone>
      <email>tpho66@bjmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strategic Support Force Specialty Medical Center</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Aihong Wang, MD</last_name>
      <phone>+86 13671365441</phone>
      <email>13671365441@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 3th Medical Center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 4th Medical Center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shinan Yi, MD</last_name>
      <phone>+86 13381326132</phone>
      <email>13381326132@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 5th Medical Center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yi Fang, MD</last_name>
      <phone>+86 13641223053</phone>
      <email>fangyi307@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 6th Medical Center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hebin Yao, MD</last_name>
      <phone>+86 18600310161</phone>
      <email>2899816158@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 7th Medical Center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xingguang Zhang, MD</last_name>
      <phone>+86 13161379221</phone>
      <email>13161379221@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 8th Medical Center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jing Shen, MD</last_name>
      <phone>+86 13522578170</phone>
      <email>shenjingshenhua@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Medical Center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yiming Mu, MD</last_name>
      <phone>+86 13910580089</phone>
      <email>muyiming@301hospital.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Kuang, MD</last_name>
      <phone>+86 13802511168</phone>
      <email>endometa@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dingyu Chen, MD</last_name>
      <phone>+86 13829706430</phone>
      <email>807235924@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Red Cross Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianmin Ran, MD</last_name>
      <phone>+86 13826267656</phone>
      <email>ranjm@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yaoming Xue, MD</last_name>
      <phone>+86 13926066999</phone>
      <email>yaoming.xue@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Yan, MD</last_name>
      <phone>+86 18922182813</phone>
      <email>hfxyl@163.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guiyang First People's Hospital</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Lu, MD</last_name>
      <phone>+86 13984176171</phone>
      <email>gyluwei925@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guiyang Second People's Hospital</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiajia Tian, MD</last_name>
      <phone>+86 13984152680</phone>
      <email>437393510@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Miao Zhang, MD</last_name>
      <phone>+86 13595008067</phone>
      <email>20057544@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qian Zhang, MD</last_name>
      <phone>+86 18685418777</phone>
      <email>5833125@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qiu Zhang, MD</last_name>
      <phone>+86 13965015060</phone>
      <email>aynfmk@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianhua Ma, MD</last_name>
      <phone>+86 13805150781</phone>
      <email>majianhua@china.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NanjingNanjing Drum Tower Hospital( the Affiliated Hospital of Nanjing University Medical School)</name>
      <address>
        <city>Nanjin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dalong Zhu, MD</last_name>
      <phone>+86 13805150781</phone>
      <email>zhudalong@nju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantong First People's Hospital</name>
      <address>
        <city>Nantong</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xueqin Ma, MD</last_name>
      <phone>+86 13813609566</phone>
      <email>wngxueqin108@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao Eighth People's Hospital</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haiyan Wang, MD</last_name>
      <phone>+86 15705321593</phone>
      <email>13573837993@163.cm</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao Third People's Hospital</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dongming Hu, MD</last_name>
      <phone>+86 18562786987</phone>
      <email>hudongming66@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yangang Wang, MD</last_name>
      <phone>+86 18661807293</phone>
      <email>wangyg1966@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Rizhao</name>
      <address>
        <city>Rizhao</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Renlian Guan, MD</last_name>
      <phone>+86 13563336878</phone>
      <email>grenlian@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingpu Branch of Zhongshan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Min Zhang, MD</last_name>
      <phone>+86 13681622338</phone>
      <email>zhangmin730713@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Minhang District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jialin Yang, MD</last_name>
      <phone>+86 18918169025</phone>
      <email>jialinyang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Xuhui District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhiwen Liu, MD</last_name>
      <phone>+86 13774454549</phone>
      <email>liuzhiwen1203@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wusong Hospital, Zhongshan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Zhang, MD</last_name>
      <phone>+86 13361952555</phone>
      <email>13361952555@189.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaoying Li, MD</last_name>
      <phone>+86 13651913857</phone>
      <email>li.xiaoying@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ji Hu, MD</last_name>
      <phone>+86 13771780309</phone>
      <email>huji@suda.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bimin Shi, MD</last_name>
      <phone>+86 13862569825</phone>
      <email>shibimin@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou Second People's Hospita</name>
      <address>
        <city>Taizhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Caifeng Qian, MD</last_name>
      <phone>+86 15951140281</phone>
      <email>479146061@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weihai Municipal Hospital</name>
      <address>
        <city>Weihai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yachao Yang, MD</last_name>
      <phone>+86 18660377177</phone>
      <email>790587538@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ling Gao, MD</last_name>
      <phone>+86 15927469449</phone>
      <email>gaoling.uk@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Wuhan</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hong Mao, MD</last_name>
      <phone>+86 18971015462</phone>
      <email>maohong8787@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College Of HUST</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xuefeng Yu, MD</last_name>
      <phone>+86 13986070673</phone>
      <email>xfyu188@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan No. 1 Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Mingsong Gao, MD</last_name>
      <phone>+86 18971069729</phone>
      <email>gaoms72@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan No. 3 Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Wu, MD</last_name>
      <phone>+86 13407101031</phone>
      <email>luodanwu@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan No. 4 Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Mei Lin, MD</last_name>
      <phone>+86 18171193607</phone>
      <email>lmei2007@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Changjiang Ying, MD</last_name>
      <phone>+86 13914888751</phone>
      <email>ycj321651@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yixing People's Hospital</name>
      <address>
        <city>Yixing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liyun Wang, MD</last_name>
      <phone>+86 139 6151 9301</phone>
      <email>staff532@yxph.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhenjiang First People's Hospital</name>
      <address>
        <city>Zhenjiang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chenguang Wu, MD</last_name>
      <phone>+86 13852943288</phone>
      <email>wcqzj1128@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Zunyi Medical University</name>
      <address>
        <city>Zunyi</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Liao, MD</last_name>
      <phone>+86 13087877099</phone>
      <email>liaoxin8618@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zunyi First People's Hospital</name>
      <address>
        <city>Zunyi</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chengyan Jiang, MD</last_name>
      <phone>+86 13765244671</phone>
      <email>47588560@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://med.wanfangdata.com.cn/Paper/Detail?dbid=WF_QK&amp;id=PeriodicalPaper_zhtnb202104005</url>
    <description>Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)</description>
  </link>
  <link>
    <url>https://care.diabetesjournals.org/content/44/Supplement_1</url>
    <description>Standards of Medical Care in Diabetes-2021. Diabetes Care.</description>
  </link>
  <reference>
    <citation>Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, Wen C, Chen CH, Kao CW, Tsao CK, Wu X. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017 Aug;92(2):388-396. doi: 10.1016/j.kint.2017.01.030. Epub 2017 Jun 1.</citation>
    <PMID>28577854</PMID>
  </reference>
  <reference>
    <citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.</citation>
    <PMID>26378978</PMID>
  </reference>
  <reference>
    <citation>Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.</citation>
    <PMID>28605608</PMID>
  </reference>
  <reference>
    <citation>Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.</citation>
    <PMID>30415602</PMID>
  </reference>
  <reference>
    <citation>Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.</citation>
    <PMID>30990260</PMID>
  </reference>
  <reference>
    <citation>Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23.</citation>
    <PMID>32966714</PMID>
  </reference>
  <reference>
    <citation>McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.</citation>
    <PMID>31535829</PMID>
  </reference>
  <reference>
    <citation>Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013 Feb 20;11:43. doi: 10.1186/1741-7015-11-43. Erratum in: BMC Med. 2013;11:193.</citation>
    <PMID>23425012</PMID>
  </reference>
  <reference>
    <citation>Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011 Oct;13(10):928-38. doi: 10.1111/j.1463-1326.2011.01434.x.</citation>
    <PMID>21672123</PMID>
  </reference>
  <reference>
    <citation>Guo K, Zhang L, Zhao F, Lu J, Pan P, Yu H, Bao Y, Chen H, Jia W. Prevalence of chronic kidney disease and associated factors in Chinese individuals with type 2 diabetes: Cross-sectional study. J Diabetes Complications. 2016 Jul;30(5):803-10. doi: 10.1016/j.jdiacomp.2016.03.020. Epub 2016 Mar 17.</citation>
    <PMID>27068269</PMID>
  </reference>
  <reference>
    <citation>Shikata K, Kodera R, Utsunomiya K, Koya D, Nishimura R, Miyamoto S, Tajima N; JDCP study group. Prevalence of albuminuria and renal dysfunction, and related clinical factors in Japanese patients with diabetes: The Japan Diabetes Complication and its Prevention prospective study 5. J Diabetes Investig. 2020 Mar;11(2):325-332. doi: 10.1111/jdi.13116. Epub 2019 Sep 25.</citation>
    <PMID>31317670</PMID>
  </reference>
  <reference>
    <citation>Mok KY, Chan PF, Lai LKP, Chow KL, Chao DVK. Prevalence of diabetic nephropathy among Chinese patients with type 2 diabetes mellitus and different categories of their estimated glomerular filtration rate based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation in primary care in Hong Kong: a cross-sectional study. J Diabetes Metab Disord. 2019 Nov 15;18(2):281-288. doi: 10.1007/s40200-018-00382-y. eCollection 2019 Dec.</citation>
    <PMID>31890652</PMID>
  </reference>
  <reference>
    <citation>Jitraknatee J, Ruengorn C, Nochaiwong S. Prevalence and Risk Factors of Chronic Kidney Disease among Type 2 Diabetes Patients: A Cross-Sectional Study in Primary Care Practice. Sci Rep. 2020 Apr 10;10(1):6205. doi: 10.1038/s41598-020-63443-4.</citation>
    <PMID>32277150</PMID>
  </reference>
  <reference>
    <citation>Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, Langkilde AM, Heerspink HJL. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019 Jun;7(6):429-441. doi: 10.1016/S2213-8587(19)30086-5. Epub 2019 Apr 13.</citation>
    <PMID>30992195</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 11, 2021</last_update_submitted>
  <last_update_submitted_qc>September 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Great Physician Commonweal Foundation</investigator_affiliation>
    <investigator_full_name>Yiming Mu</investigator_full_name>
    <investigator_title>Director of department</investigator_title>
  </responsible_party>
  <keyword>SGLT2 inhibitors</keyword>
  <keyword>Diabetic Kidney Disease</keyword>
  <keyword>Albuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant level data and measurements including tables, figures, and appendices or supplementary material that support the results presented in a manuscript will be shared 6 months after publication.</ipd_description>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Researches should send a proposal to muyiming@301hospital.com.cn. If the proposal is methodologically sound, feasible and approved by the principal investigator, data requestor could gain access after signing a data access agreement.</ipd_access_criteria>
    <ipd_url>http://www.bgpcf.net</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

